About 38% efficacy, according to sox's research in his post. Despite what some bashers may try to say, that drug is not very effective and represents no competition if Bril-OM is shown to work. The bar for approval seems to be set very low, if that difficult-to-administer drug got approved with such poor efficacy.

http://investorshangout.com/post/view?id=4096967

And don't you think some big pharma would be just delighted to strike a deal for a drug like Bril-OM for which no viable alternative exists?